14:21 uur 31-03-2017

Eerste gezamenlijke definitie van patiëntgerichtheid van AstraZeneca, patiënten en zorgverleners gepubliceerd in Brits medisch tijdschrift

CAMBRIDGE, England–(BUSINESS WIRE)– AstraZeneca heeft vandaag bekendgemaakt dat BMJ Innovations de eerste collaboratieve definitie van patiëntgerichtheid voor de farmaceutische industrie heeft gepubliceerd. Patiënten en zorgverleners  hebben de definitie gezamenlijk opgesteld onder leiding van AstraZeneca en belangenbehartigers van patiënten. Die omschrijving garandeert een verregaand begrip van de behoeften en waarden van patiënten.  BMJ Innovations heeft ook tien samenhangende patiëntgerichte principes gepubliceerd, zodat de farmaceutische industrie consistente ijkpunten heeft voor betekenisvolle en wederzijds bevorderlijke betrokkenheid bij patiënten. Bredere tests van deze resultaten onder Amerikaanse en Europese patiënten bevestigden de validiteit van deze principes.



First Collaborative Definition of Patient Centricity, Co-created by AstraZeneca with Patients and Carers, Is Published in British Medical Journal

CAMBRIDGE, England–(BUSINESS WIRE)– AstraZeneca today announced that BMJ Innovations has published the first collaborative definition of patient centricity for the pharmaceutical industry. The definition was co-developed with patients and caregivers using research led by AstraZeneca and patient community advocates to ensure a deep understanding of patient needs and values. Ten associated patient-centric principles were also identified and published in BMJ Innovations to provide the pharmaceutical industry with a consistent reference point to sustain meaningful and mutually beneficial engagement with patients. Wider testing of these outputs among US and European patient communities confirmed their validity.

This Smart News Release features multimedia. View the full release here:http://www.businesswire.com/news/home/20170331005036/en/

The research published in BMJ defines patient centricity as: “Putting the patient first in an open and sustained engagement of the patient to respectfully and compassionately achieve the best experience and outcome for that person and their family.” This definition encompassed five clear points of importance to patients that were identified and validated through the research: (1) inclusiveness; (2) sharing goals that are patient and family centred; (3) empowering patients to take control of their own health; (4) working in a way that shows respect, compassion and openness; and (5) working in partnership.

Patricia Furlong, President and CEO of Parent Project Muscular Dystrophy and a co-author of the research, said: “This is a landmark project for the pharmaceutical industry. As patients and caregivers, we are eager to see industry engaging with patients in a meaningful way to deliver what we actually want. This definition and set of guiding principles creates a clear signpost for industry by establishing a goal for how to meaningfully put patients at the centre of work by involving them in decision-making in a way that truly benefits them.”

Guy Yeoman, Vice President, Patient Centricity at AstraZeneca, said: “We asked patients what they wanted our industry to focus on, and we heard very clearly that they wanted us to stop concentrating solely on what we deliver, and think about how we deliver it. If we get the ‘how’ right, then the ‘what’ will be so much more meaningful and impactful for patients. For the first time, we believe we have a definitive direction for how patient engagement should be conducted in the way we, as an industry, research and develop our medicines”.

AstraZeneca’s research included extensive engagement with patients, including interviews with individual patients and patient organisations, and interaction with patients through an online forum and patient advisory boards. Healthcare providers and payers also provided input on patient needs. Following the data collection, researchers conducted two patient workshops designed to develop a definition of patient centricity and identify relevant principles for pharmaceutical companies that are most important to patients. Developed by a total of 22 patients and caregivers across a wide variety of conditions from North America and Europe, the principles were also validated via 470 and 703 patients in the PatientsLikeMe and Carenity online networks, respectively.

Reference: Yeoman G, Furlong P, Seres M , et al. Defining patient centricity with patients for patients and caregivers: a collaborative endeavor. BMJ Innovations Published Online First: 24 March 2017. doi: 10.1136/bmjinnov-2016-000157


About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visitwww.astrazeneca.com and follow us on Twitter @AstraZeneca.

Intended audiences

This press release is issued from AstraZeneca Corporate Headquarters in Cambridge, UK and is intended to provide information about our global business. Please be aware that any information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where AstraZeneca conducts business.


Media Enquiries
Julie Saunders
+44 776 656 5798
Rob Skelding
+44 203 749 5821

Check out our twitter: @NewsNovumpr